Pantop%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion. ## Primary Indications * Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis. * Healing of duodenal ulcers. * H. pylori eradication (in combination therapy). * Zollinger-Ellison syndrome and other hypersecretory conditions. ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. Duration varies based on healing, often 4-8 weeks. * **Duodenal Ulcer Healing:** 40 mg orally or intravenously once daily for up to 4 weeks. * **H. pylori Eradication (Triple Therapy):** 40 mg orally twice daily for 7-14 days, in combination with antibiotics (e.g., amoxicillin and clarithromycin or metronidazole and clarithromycin). * **Zollinger-Ellison Syndrome:** Start at 40 mg orally or intravenously once daily. Doses may be titrated up to 240 mg daily (divided if exceeding 160 mg/day) based on response. ## Pediatric Dosing * **GERD/Erosive Esophagitis (1 month to 5 years):** 0.7-1.4 mg/kg orally once daily, not to exceed 20 mg/day. * **GERD/Erosive Esophagitis (5 years to 16 years):** 20-40 mg orally once daily. * **Zollinger-Ellison Syndrome (pediatric patients):** Dosing is individualized based on clinical response; limited data available. ## Dose Adjustments No dose adjustment is typically required for hepatic impairment, although some sources suggest caution or a reduced dose (e.g., 20 mg daily) in severe impairment. No dose adjustment for renal impairment. ## Contraindications * Known hypersensitivity to pantoprazole, other PPIs, or any component of the formulation. ## Adverse Effects Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness. Less Common/Serious: * **Long-term use associated risks:** Increased risk of fractures (hip, wrist, spine), Clostridium difficile-associated diarrhea, vitamin B12 deficiency, hypomagnesemia (can be severe and symptomatic), kidney disease (acute interstitial nephritis). * **Acute:** Severe allergic reactions (anaphylaxis), liver enzyme elevations. ## Key Drug Interactions * **Drugs requiring gastric acid for absorption:** Antiretrovirals (e.g., rilpivirine, atazanavir), antifungals (e.g., ketoconazole, itraconazole), certain tyrosine kinase inhibitors. Pantoprazole can decrease absorption. * **CYP2C19 substrates:** May increase levels of drugs like clopidogrel (though clinical significance is debated), diazepam, and phenytoin. * **Methotrexate:** PPIs may increase methotrexate levels; monitor for toxicity. ## Monitoring * Electrolytes (especially magnesium and potassium) with long-term therapy. * Renal function with long-term therapy. * Signs and symptoms of C. difficile infection. * Bone mineral density screening may be considered for patients at risk with long-term PPI use. ## Clinical Pearls * Administer oral pantoprazole 30-60 minutes before a meal. * For IV administration, reconstitute and dilute as per manufacturer instructions. Infusion over 15 minutes. * IV to PO switch is generally appropriate once clinically indicated. * While generally safe, be mindful of potential risks associated with prolonged PPI use, especially in elderly patients or those with comorbidities. *** **Disclaimer:** This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines for complete details and to ensure patient safety. Dosing may vary based on specific patient factors, institutional protocols, and evolving clinical evidence.